BioCardia, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for BCDA, updated each market day.
BCDA AI Sentiment
AI predicts BioCardia, Inc. Common Stock stock is likely to increase over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About BioCardia, Inc. Common Stock
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
Sector
Exchange
Market Cap
$12,800,235
Cap Tier
Employees
21
Headquarters
SUNNYVALE, CA
Listed Since
Oct. 25, 1995
Website
BCDA Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
BCDA Volatility
BioCardia, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
